EMPARA FORTE TAB combines two clinically proven antidiabetic agents—Glimepiride, a sulfonylurea derivative, and Metformin Hydrochloride (Sustained Release), a biguanide—to provide comprehensive glycemic control in patients with Type 2 Diabetes Mellitus. The synergistic action of these two drugs makes EMPARA FORTE TAB highly effective, especially in patients who require more than monotherapy to manage their blood glucose levels.
This formulation addresses both insulin resistance and beta-cell dysfunction, the two core pathophysiological defects in Type 2 diabetes. Glimepiride stimulates pancreatic beta cells to increase insulin secretion, while Metformin reduces hepatic glucose production and improves peripheral glucose uptake.
Developed under the highest standards of pharmaceutical manufacturing at WHO-GMP and ISO-certified units of BluepillExpress, EMPARA FORTE TAB is suitable for third-party labeling, institutional supply, and international regulatory registrations. It is available in bulk quantities and supports full regulatory documentation (COA, MSDS, Stability Data, CTD Format Dossier).
✅ Therapeutic Indications
Type 2 Diabetes Mellitus (T2DM), when monotherapy is insufficient
Patients with high fasting and postprandial glucose levels
Diabetic patients with overweight or insulin resistance
Dual-drug therapy in progressive T2DM as per ADA/EASD guidelines
✅ Pharmacology and Mechanism of Action
Glimepiride:
Stimulates insulin release by closing ATP-sensitive potassium channels in pancreatic beta cells.
Enhances insulin receptor sensitivity in peripheral tissues.
Metformin (SR):
Decreases hepatic gluconeogenesis (glucose production).
Improves peripheral glucose uptake and utilization.
Reduces intestinal absorption of glucose.
Together, these agents offer fast onset (from Glimepiride) and sustained glucose control (from Metformin SR).
Description provided by bluepill express.
FIEO Registered
Export Ready
